This announcement is a separate document:
龙津药业：董事会审计委员会对会计师事务所2023年度履职情况评估总结报告
Kunming Longjin Pharmaceutical: Summary report of the Board Audit Committee on the evaluation of the accounting firm's performance in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.